STOCK TITAN

Arcutis Biotherapeutics (ARQT) director receives RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Arcutis Biotherapeutics director Christopher Peetz reported equity awards and holdings. On July 15, 2026 he received 4,315 RSUs, each convertible into one share upon vesting on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting, subject to continued service.

He also received stock options for 21,486 and 13,010 shares at an exercise price of $27.78 per share, vesting over time as described and expiring July 15, 2036. An additional 187,500 shares are held indirectly by The Peetz Family Trust, for which he disclaims beneficial ownership beyond his pecuniary interest.

Positive

  • None.

Negative

  • None.
Insider Peetz Christopher
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 21,486 $0.00 --
Grant/Award Stock Option (right to buy) 13,010 $0.00 --
Grant/Award Common Stock 4,315 $0.00 --
holding Common Stock -- -- --
Holdings After Transaction: Stock Option (right to buy) — 21,486 shares (Direct); Common Stock — 4,315 shares (Direct); Common Stock — 187,500 shares (Indirect, By The Peetz Family Trust)
Footnotes (1)
  1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date. Shares held by The Peetz Family Trust dated February 15, 2017, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. 1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
RSUs granted 4,315 units Restricted Stock Units granted July 15, 2026 for non-employee director service
Stock options granted 21,486 shares Underlying common shares for one option grant dated July 15, 2026
Stock options granted 13,010 shares Underlying common shares for second option grant dated July 15, 2026
Exercise price $27.78 per share Exercise price of stock options granted July 15, 2026
Option expiration 2036-07-15 Expiration date of the stock options granted to Christopher Peetz
Indirectly held shares 187,500 shares Common shares held by The Peetz Family Trust
RSU vesting reference date June 5, 2027 RSUs vest on the earlier of June 5, 2027 or immediately before the next annual meeting
Vesting commencement date July 15, 2026 Vesting Commencement Date for the 21,486-share option grant
Restricted Stock Units ("RSUs") financial
"Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
pecuniary interest regulatory
"disclaims beneficial ownership of such securities except to the extent of his pecuniary interest"
Vesting Commencement Date financial
"on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date")"
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
non-employee director regulatory
"service as a non-employee director of the Company"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What equity awards did Christopher Peetz report for ARQT on July 15, 2026?

Christopher Peetz reported 4,315 RSUs and stock options for 21,486 and 13,010 ARQT shares on July 15, 2026. The options carry a $27.78 exercise price per share and have specified multi-year vesting schedules tied to his non-employee director service.

How do the 4,315 RSUs granted to Christopher Peetz at ARQT vest?

The 4,315 RSUs vest into one ARQT share per unit on the earlier of June 5, 2027 or immediately before the next annual stockholder meeting. Vesting is conditioned on Christopher Peetz’s continued service as a non-employee director through the applicable vesting date.

What are the key terms of the stock options granted to Christopher Peetz at ARQT?

Christopher Peetz received stock options over 21,486 and 13,010 ARQT shares at a $27.78 exercise price, expiring July 15, 2036. One grant vests over four years from July 15, 2026, while the other vests 100% on the earlier of June 5, 2027 or the next annual meeting.

How many ARQT shares are held through The Peetz Family Trust?

The Peetz Family Trust holds 187,500 ARQT shares reported as indirect ownership for Christopher Peetz. He is a trustee and disclaims beneficial ownership of those securities except to the extent of his pecuniary interest, according to the filing’s trust footnote.

Does Christopher Peetz hold ARQT shares directly in addition to RSUs and options?

Yes. Following the RSU grant, Christopher Peetz is shown with 4,315 ARQT shares directly tied to RSUs and stock options for 21,486 and 13,010 underlying shares. Separately, 187,500 shares are reported as indirectly held via The Peetz Family Trust.

What is the vesting schedule for the 21,486-share ARQT option grant to Christopher Peetz?

For the 21,486-share option grant, one-third of the underlying ARQT shares vest on the first anniversary of July 15, 2026. The footnote states that 100% of these option shares will be vested and exercisable on the fourth anniversary, subject to continued director service.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Peetz Christopher

(Last)(First)(Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC.
3027 TOWNSGATE ROAD, SUITE 300

(Street)
WESTLAKE VILLAGE CALIFORNIA 91361

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Arcutis Biotherapeutics, Inc. [ ARQT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/15/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/15/2026A4,315(1)A$04,315D
Common Stock187,500IBy The Peetz Family Trust(2)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$27.7807/15/2026A21,486(3) (3)07/15/2036Common Stock21,486$021,486D
Stock Option (right to buy)$27.7807/15/2026A13,010(4) (4)07/15/2036Common Stock13,010$013,010D
Explanation of Responses:
1. Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director of the Company. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
2. Shares held by The Peetz Family Trust dated February 15, 2017, of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.
3. 1/3 each of the underlying shares subject to the option vest and become exercisable on the first annual anniversary of July 15, 2026 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the non-employee director's continued service through each applicable vesting date.
4. The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of June 5, 2027, or immediately before the next annual meeting of stockholders, subject to the director's continued service through the vesting date.
Remarks:
/s/Latha Vairavan, as Attorney-in-Fact for Christopher Peetz07/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)